Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes management.

The U.S. Food and Drug Administration is revising the labeling of all extended-release attention-deficit/hyperactivity ...

Can Hair Loss Supplements Harm Your Health? Doctors Say The Risks—Particularly To Your Liver—Are Real.

TMates Weightloss Semaglutide reviews reveal how users are losing weight with this telehealth prescription service—see if it ...

The FDA now requires ADHD extended-release drug labels to warn of weight loss risks in children under 6, urging monitoring ...

The U.S. Food and Drug Administration is revising the labeling of all extended-release attention-deficit/hyperactivity ...

Labels of all extended-release stimulants indicated for ADHD -- including certain formulations of amphetamine and ...

Some less expensive versions of popular weight loss drugs are no longer available to patients, after the Food & Drug ...

Three people share the hoops they've jumped through, financial strain they've endured and risks they've taken on in order to ...

Both semaglutide and tirzepatide for type 2 diabetes and weight loss are GLP-1 agonists, meaning they mimic the hormone.

Children younger than 6 years of age who are prescribed extended-release stimulants for attention-deficit hyperactivity disorder (ADHD) may experience ...

The FDA now requires updated labeling for all extended-release stimulant medications used to treat attention deficit hyperactivity disorder, warning of increased risk of weight loss and other side ...